Clinical Trial Update: Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 study results for etelcalcetide in hemodialysis patients with secondary hyperparathyroidism, evaluating safety, tolerability and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

Sponsor: KAI Pharmaceuticals | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED | Results posted: 2017-04-13